Preferred Label : rasagiline;
MeSH note : monoamine oxidase type-B inhibitor that is not metabolized to amphetamine derivatives;
can lead to fatal hypertensive crisis in patients who consume tyramine-rich foods;
CISMeF synonym : 1506-18-9 (rasagiline hydrochloride); 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride; AGN 1135; N-propargyl-1-aminoindan mesylate; TVP 101; TVP 1022; azilect;
MeSH synonym : N-2-propynyl-1-indanamine;
MeSH hyponym : AGN-1135; TVP1022; TVP-1022; TVP-101;
MeSH Related Number : rasagiline hydrochloride; 1506-18-9 (HCl); 1875-50-9 (rasagiline); 2V1ZE3067R;
Registry Number MeSH : 1875-50-9;
Related CAS MeSH : 2V1ZE3067R (rasagiline hydrochloride);
related registry number list (CISMeF) : 1506-18-9 (HCl);
CISMeF hyponym : chlorhydrate de rasagiline;
Is substance : O;
UNII : 003N66TS6T;
InChIKey : RUOKEQAAGRXIBM-GFCCVEGCSA-N;
Origin ID : C031967;
UMLS CUI : C0525678;
ATC code(s)
- ATC code(s)
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.ema.europa.eu/medicines/human/EPAR/rasagiline-mylan
2016
false
United Kingdom
French
English
rasagiline
levodopa
Motor fluctuations
Substance with monoamine oxidase B inhibitor mechanism of action (substance)
syndication feed
drugs, generic
Product containing precisely rasagiline 1 milligram/1 each conventional release oral
tablet (clinical drug)
monoamine oxidase inhibitors
parkinson disease
antiparkinson agents
drug therapy, combination
antiparkinson agents
indans
monoamine oxidase inhibitors
pregnancy
indans
breast feeding
drug interactions
drug labeling
drug approval
treatment outcome
drug evaluation, preclinical
tablets
administration, oral
adult
aged
rasagiline
rasagiline
summary of product characteristics
package leaflet
drug evaluation
---
https://www.ema.europa.eu/medicines/human/EPAR/Rasagiline-ratiopharm
2015
false
United Kingdom
French
English
rasagiline
levodopa
Motor fluctuations
Substance with monoamine oxidase B inhibitor mechanism of action (substance)
syndication feed
Product containing precisely rasagiline 1 milligram/1 each conventional release oral
tablet (clinical drug)
monoamine oxidase inhibitors
parkinson disease
antiparkinson agents
drug therapy, combination
antiparkinson agents
indans
monoamine oxidase inhibitors
pregnancy
indans
breast feeding
drug interactions
drug labeling
drug approval
treatment outcome
drug evaluation, preclinical
tablets
administration, oral
adult
aged
rasagiline
rasagiline
summary of product characteristics
package leaflet
drug evaluation
---
http://www.has-sante.fr/portail/jcms/c_2058016/fr/azilect
http://www.has-sante.fr/portail/jcms/c_994256/azilect
2015
false
France
French
insurance, health, reimbursement
indans
parkinson disease
treatment outcome
rasagiline
rasagiline
administration, oral
antiparkinson agents
monoamine oxidase inhibitors
evaluation of the transparency committee
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00014
2011
false
false
false
Canada
drug information
rasagiline
rasagiline
tablets
mesylates
---
http://www.has-sante.fr/portail/jcms/c_1019830/azilect-rasagiline-imao-b
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-10/azilect_-_ct8133.pdf
2010
France
French
administration, oral
antiparkinson agents
rasagiline
monoamine oxidase inhibitors
rasagiline
indans
parkinson disease
treatment outcome
indans
guidelines for drug use
evaluation of the transparency committee
---
http://www.fmoq.org/Lists/FMOQDocumentLibrary/fr/Le%20M%C3%A9decin%20du%20Qu%C3%A9bec/Archives/2000%20-%202009/087-089info-comprim%C3%A9e1208.pdf
2008
Canada
French
antiparkinson agents
indans
neuroprotective agents
parkinson disease
rasagiline
indans
journal article
---
http://www.has-sante.fr/portail/jcms/c_713106/azilect
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-11/azilect_-_ct-5435.pdf
2008
France
French
rasagiline
monoamine oxidase inhibitors
administration, oral
indans
treatment outcome
rasagiline
parkinson disease
drug therapy, combination
levodopa
indans
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/AZILECT
2007
false
United Kingdom
French
English
syndication feed
Product containing precisely rasagiline 1 milligram/1 each conventional release oral
tablet (clinical drug)
Contraindications, Procedure
monoamine oxidase inhibitors
parkinson disease
indans
monoamine oxidase inhibitors
antiparkinson agents
drug therapy, combination
antiparkinson agents
antiparkinson agents
antiparkinson agents
antiparkinson agents
antiparkinson agents
indans
indans
indans
indans
monoamine oxidase inhibitors
monoamine oxidase inhibitors
monoamine oxidase inhibitors
monoamine oxidase inhibitors
pregnancy
indans
breast feeding
drug interactions
drug labeling
drug approval
treatment outcome
drug evaluation, preclinical
tablets
administration, oral
adult
aged
rasagiline
rasagiline
indans
summary of product characteristics
package leaflet
drug evaluation
Contraindications, Drug
---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Azilect_March-28-07_fr.pdf
2007
Canada
French
parkinson disease
indans
monoamine oxidase inhibitors
neuroprotective agents
rasagiline
rasagiline
indans
drug evaluation
---
